Business
Second Australian GeneICE Patent Granted
Second Australian GeneICE Patent Granted.
About this update from Valirx Plc
[{"type":"text","content":"\n \nFor immediate release: 28 May 2008, 07:00\n\n VALIRX PLC \n\n (\"ValiRx\" or the \"Company\") \n\n Second Australian GeneICE Patent Granted \n\nValiRx (AIM: VAL), the cancer therapeutics and diagnostics company, today\nannounces that its proprietary gene-silencing technology, GeneICE, has secured\na second patent from the Australian Patent Office.\n\nThis additional Australian patent, along with the similar European patent\ngranted in August 2007, protects the design of the GeneICE molecules used by\nthe Company. It supplements the original Australian patent, granted in January\n2008, which - in line with the US patent issued in April 2007 - protects the\nunderlying GeneICE technology platform.\n\nValiRx holds the worldwide exclusive commercial rights to GeneICE through its\nsubsidiary, Cronos Therapeutics Ltd (\"Cronos\").\n\nDr Satu Vainikka, CEO of ValiRx, commented:\n\n\"This second Australian patent adds a further layer of protection for our\nGeneICE technology in that market, widening the potential global opportunities\nthat exist for our epigenetic based approach to treat cancer.\"\n\n --Ends-- \n\nAbout ValiRx plc\n\nValiRx is a biopharmaceutical company that is building a portfolio of\ncomplementary cancer-related diagnostic and therapeutic products based on\npatented technologies.\n\nThe Company's products are rooted in the epigenomic analysis and treatment of\ncancer. Epigenetics is the emerging science of how, when and why genes are\nswitched \"on\" or \"off\" in the body. By knowing which genes are responsible for\na specific disease, doctors can target the therapy to that particular gene. At\nthe same time, the technology has the potential to also be used for screening\npurposes in identifying individuals at risk of developing disease based on\ntheir epigenetic make-up.\n\nValiRx currently holds a worldwide exclusive license for Nucleosomics, the\nearly stage oncology diagnostics technology, and has majority stakes in Cronos\nTherapeutics Ltd (\"Cronos\") and ValiBIO SA:\n\n * Cronos holds worldwide exclusive licenses to two innovative and potentially\n market changing technologies, GeneICE and HyperGenomicsTM, and is\n developing further novel cancer therapies;\n \n * ValiBIO SA is a Belgium joint venture between ValiRx and BIO.be focusing on\n the development and commercialisation of products in the epigenom...